Clinical Trials Browser

Breast Neoplasms, Meningeal Carcinomatosis

NCT04661384 2026-03-05

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

Phase 1 Active not recruiting

10 enrolled

CNS

Ependymoma, Glioblastoma, Medulloblastoma, Meningeal Carcinomatosis

NCT03719768 2026-03-02

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Phase 1 Completed

16 enrolled

CNS

Brain Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT06663306 2026-03-02

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Phase 1 Recruiting

19 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT06058988 2026-02-23

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Phase 2 Recruiting

30 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT04588545 2026-02-09

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Phase 1/2 Recruiting

39 enrolled

CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT05184816 2026-01-30

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Phase 1 Recruiting

35 enrolled

CNS

Recurrence, Meningeal Carcinomatosis

NCT06296745 2026-01-30

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Phase 2 Recruiting

36 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06592092 2026-01-29

Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors

Phase NA Completed

3 enrolled

CNS

Meningeal Carcinomatosis

NCT07348965 2026-01-16

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Phase NA Not yet recruiting

42 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06500481 2026-01-14

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Phase 3 Recruiting

115 enrolled

BreastCNSThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT06724926 2026-01-02

Concurrent Azeliragon With Craniospinal Irradiation

Phase 1 Recruiting

32 enrolled

CNS

Glioma, Meningeal Carcinomatosis

NCT07304739 2025-12-26

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Phase 2 Recruiting

30 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Clinical Trials

Exo-LCR

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Concurrent Azeliragon With Craniospinal Irradiation

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases